## FORM 1 - ANTI-VIRAL DRUGS **ID Number** Visit No. DATE DAY YEAR Jan ○ Feb 0 0 0 0 0 0 COMPLETE THE FOLLOWING FOR EACH DRUG LISTED IN 11111 1 1 1 ○ Mar 0) (0 QUESTION 18.A(2). 2 2 2 2 2 2 (2) (2) 10 (1) 94 O Apr 3 3 3 3 3 (3)(3) ○ May 20 (2) Acyclovir (ACV, Zovirax) OddI (dideoxyinosine, (4) (4) 4 4 4 4 4 Jun 30 3 O AL-721 Didanosine, Videx) 5 5 5 5 5 (5) (5) O Jul (4) Alpha Interferon OddI/ddC 6666 (6) (6) O Aug (5) Ampligen O Dextran-Sulfate 77777 (7) (7) Sep 6 AZT (Azidothymidine, Foscarnet (8) (8) (8) (8) (8) Oct (7) Compound S, Retrovir, (Phosphonoformate, PFA) 9 9 9 9 (9) (9) O Nov (8) Zidovudine, ZDV) O Peptide T (9) Dec Recombinant CD4 AZT/ddC O AZT/ddI Ribavirin ○ AZT/ddI/ddC Name of Drug: **Drug Code** O Beta Interferon Other -0 100 200 300 400 500 600 700 800 900 0 10 20 30 40 50 60 70 80 90 0 d4T ddC (dideoxycytidine, HIVID, 0 1 2 3 4 5 6 7 8 9 Zalcitabine) You said you were taking (DRUG) since your last visit: 1.A. Did you take this drug as part of a research study? 2. Since your last visit in (MONTH), how long have you used this (DRUG)? O NO (GO TO Q2) O YES One week or less More than 1 week but less than 1 month 1 - 2 months B. Was this study one in which you may have taken a 3 - 4 months placebo (not the actual drug) or in which you were 5 - 6 months blinded to the treatment? More than 6 months ONO O YES 3. Did you alternate your use of this drug with another anti-viral drug? C. Was this part of the AIDS Clinical Trial Group (ACTG)? ONO (GO TO Q5) ONO (GO TO F) O YES O YES O DON'T KNOW (GO TO F) 4. If YES, how often did you alternate these drugs? More often than weekly D. If YES, do you know the ACTG number? Weekly (GO TO F) ONO Every two weeks (GO TO Q8) YES Monthly Less often than monthly Other alternating schedule E. What is the number of that study? 0 100 200 300 400 500 600 700 800 900 5. Did you stop altogether or decrease your daily dose 0 10 20 30 40 50 60 70 80 90 of (DRUG) since your last visit? 0 1 2 3 4 5 6 7 8 9 ONO (GO TO Q8) () YES F. Are you currently taking this drug as part of the research study? ONO YES Please continue on the other side. (STOP, GO TO NEXT DRUG)

Mark Reflex® by NCS EM-155110:321

Printed in U.S.A.

6.	Why did you stop t	taking or decre	ease this drug?		
	(MARK ALL THAT APPLY)				
	Low white blood cells (low neutrophils) Anemia (low red blood cells/low hemoglobin) Bleeding Dizziness/Headaches Nausea/Vomiting Abdominal pain (pancreatitis/abdominal bloating/cramps) Muscle pain or weakness (myopathy/myositis/muscle cramps/spasms) Burning/tingling in extremities (neuropathy/neuritis/numbness) Hospitalized Personal decision Prescription changes by physician Too expensive Too much bother, inconvenient (ran out/vacation/unable to fill prescription) Other, specify:				
	1)				
	3)				
7	7. Did you restart or increase your use of this drug?				
7.	NO NO	ncrease your	use of this drug?		
	YES				
<ol> <li>What is the most recent total daily dose that you took? For example, 200 mg 3 times per day = 600 mg.</li> </ol>					
1	TOTAL DAILY DOSE	UNITS CODE	(RECORD PARTICIPANT'S COMPLETE RESPONSE)		
	0000	0 0	ODon't Know		
	200 20 2 200 20 2	20 2			
	600 800 30 3 600 40 4	30 3 40 4			
	600 600 60 6	50 5			
	600 600 60 600 70 7	60 6 70 7			
	<b>600 80 8</b>	80 8			
	900 90 9	99 9			
9.	9. Are you currently taking this drug?				
	○ NO ○ YES	gc ala	<b>y</b> -		